INCY Share Price

Open 104.76 Change Price %
High 106.53 1 Day -5.25 -4.90
Low 99.72 1 Week 2.03 2.03
Close 101.96 1 Month 9.80 10.63
Volume 1937258 1 Year -8.14 -7.39
52 Week High 118.49
52 Week Low 55.00
INCY Important Levels
Resistance 2 108.27
Resistance 1 105.67
Pivot 102.74
Support 1 98.25
Support 2 95.65
NASDAQ USA Most Active Stocks
FNFG 10.18 -0.20%
DELL 13.86 0.22%
RFMD 16.59 -2.07%
RIMM 13.03 0.39%
BBEP 0.12 0.00%
GTAT 0.44 0.00%
SUSQ 14.20 -0.77%
MU 20.45 7.29%
MU 20.45 7.29%
MU 20.45 7.29%
More..
NASDAQ USA Top Gainers Stocks
LOCM 0.09 50.00%
ANTH 2.03 38.10%
EMKR 8.45 31.01%
MBLX 0.32 28.00%
BSDM 0.62 26.53%
SNTA 0.34 25.93%
OTT 2.39 25.13%
HTCO 8.00 23.08%
ATEA 1.95 21.88%
ATEA 1.95 21.88%
More..
NASDAQ USA Top Losers Stocks
TXCC 0.01 -95.00%
HCIIP 10.10 -67.52%
CRMB 0.27 -57.81%
KIOR 0.03 -57.14%
OSH 0.26 -49.02%
OSH 0.26 -49.02%
DVOX 0.05 -44.44%
PRXI 0.21 -43.24%
TRGT 0.96 -41.46%
QKLS 0.12 -36.84%
More..

Incyte Corporation (NASDAQ: INCY)

INCY Technical Analysis 4
As on 7th Dec 2016 INCY Share Price closed @ 101.96 and we RECOMMEND Strong Buy for LONG-TERM with Stoploss of 82.13 & Buy for SHORT-TERM with Stoploss of 95.27 we also expect STOCK to react on Following IMPORTANT LEVELS.
INCY Target for December
1st Target up-side 117.03
2nd Target up-side 127.32
3rd Target up-side 137.61
1st Target down-side 87.67
2nd Target down-side 77.38
3rd Target down-side 67.09
INCY Other Details
Segment EQ
Market Capital 2323686912.00
Sector Healthcare
Industry Biotechnology
Offical website http://www.incyte.com
INCY Address
INCY
Experimental Station
Route 141 & Henry Clay Road
Wilmington, DE 19880
United States
Phone: 302-498-6700
Interactive Technical Analysis Chart Incyte Corporation ( INCY NASDAQ USA )
Java support must be enabled in order to display FnCharts.
You can download Java from http://www.java.com
Your Comments and Response on Incyte Corporation
INCY Business Profile
Incyte Corporation (Incyte) is a biopharmaceutical company focused on the discovery, development and commercialization of small molecule drugs to treat serious unmet medical needs. Its advanced compound, JAKAFI (ruxolitinib), also known as INCB18424 and INC424, is an oral Janus associated kinase (JAK) inhibitor used for the treatment for patients with intermediate or high-risk myelofibrosis (MF), including primary MF, post-polycythemia vera MF and post-essential thrombocythemia MF. The Company has a second oral JAK1 and JAK2 inhibitor, LY3009104 (INCB28050), which is subject to a collaboration agreement with Eli Lilly and Company in which Lilly received worldwide development and commercialization rights for the compound for inflammatory and autoimmune diseases. In November 2011, JAKAFI became commercially available in the United States and is being marketed in the United States.